Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 152 for your search:
Cancer Type/Condition:
Brain tumor, adult: Glioblastoma
Country:
U.S.A.
Trial Type:
Treatment
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
RTOG-0825
, RTOG 0825, NCT00884741
2.
Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
EF-14
, NCT00916409
3.
A Phase I/II Study of the Photon Radiosurgery System
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
2 to 32
Sponsor:
Other
Protocol IDs:
CNS 0201
, NCT00179907
4.
GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
UCSF-05103
, 05103, UCSF-H41995-27311-01, NCT00293423
5.
ZD6474 in Treating Patients With Recurrent or Progressive Gliomas
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-06-C-0063
, NCI-P6680, NCT00293566
6.
Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCCTG-N0572
, N0572, NCT00329719
7.
Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
501007705
, NCT00301418
8.
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
ABTC-05-02
, NABTC-05-02, NCT00335764
9.
Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
ABTC-0504
, NABTT-0504, NABTT-0504, NCT00379080
10.
AQ4N in Combination With Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
021-003
, NCT00394628
11.
Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
06-377
, IRUSZACT0018, NCT00441142
12.
Intracerebral Clysis in Treating Patients With Recurrent Primary Brain Tumors
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
1 to 120
Sponsor:
Other
Protocol IDs:
R01 CA 89395-01
, Topotecan, Brain Tumors, Intracerebral Clysis, NCT00452959
13.
Radiosurgery for Glioblastoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Over 65
Sponsor:
Other
Protocol IDs:
2006P-000464
, NCT00456612
14.
Hydroxychloroquine, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
ABTC-0603
, NABTT-0603, 0603, NCT00486603
15.
Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
UCLA-0604104
, OSI3781s, NCT00509431
16.
VNP40101M and Temozolomide in Treating Patients With Progressive or Relapsed Malignant Glioma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Over 18
Sponsor:
NCI
Protocol IDs:
NU07C1
, NU 07C1, NCT00516282
17.
Safety and Efficacy Study of REOLYSIN® in the Treatment of Recurrent Malignant Gliomas
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
REO 007
, NCT00528684
18.
Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCCTG-N057K
, N057K, NCT00553150
19.
Vorinostat, Isotretinoin and Carboplatin in Adults With Recurrent Glioblastoma Multiforme (GBM)
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
2006-0709
, NCT00555399
20.
Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Recovering From Lymphopenia Caused by Temozolomide
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Diagnostic, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
DUMC-PRO00000580
, PRO00000580, DUMC-SPORE Project 3, NCT00627224
21.
BSI-201 and Temozolomide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
ABTC-0703
, NABTT-0703, NABTT-0703, NCT00589576
22.
Temozolomide, Carmustine, O6-Benzylguanine, Radiation Therapy, and an Autologous Stem Cell Transplant in Treating Patients with Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
FHCRC-2000.00
, FHCRC-2000.00, 8357, FHCRC-IR-6259, NCT00669669
23.
Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
MGH-07-344
, 07-344, 8030, NCT00662506
24.
Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
2008-0059
, NCT00734526
25.
ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
ABTC-0801
, NABTT-0801, 0801, ABBOTT-M10-190, NCT00770471
Select All on Page
1
Help with Results
